Publicacións en colaboración con investigadores/as de University of Amsterdam (11)

2024

  1. MOXD1 is a lineage-specific gene and a tumor suppressor in neuroblastoma

    Science Advances, Vol. 10, Núm. 25

2023

  1. Federating Medical Deep Learning Models from Private Jupyter Notebooks to Distributed Institutions

    Applied Sciences (Switzerland), Vol. 13, Núm. 2

2022

  1. Federating Unlabeled Samples: A Semi-supervised Collaborative Framework for Whole Slide Image Analysis

    Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)

2021

  1. A g316a polymorphism in the ornithine decarboxylase gene promoter modulates mycn‐driven childhood neuroblastoma

    Cancers, Vol. 13, Núm. 8

  2. Study protocol: The ear-nose-throat (ENT) prospective international cohort of patients with primary ciliary dyskinesia (EPIC-PCD)

    BMJ Open, Vol. 11, Núm. 10

2018

  1. Genomic amplifications and distal 6q loss: Novel markers for poor survival in high-risk neuroblastoma patients

    Journal of the National Cancer Institute, Vol. 110, Núm. 10

  2. Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma

    Cancer Research, Vol. 78, Núm. 20, pp. 5958-5969

2014

  1. CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients

    PLoS ONE, Vol. 9, Núm. 12

  2. Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma

    Pediatric Blood and Cancer, Vol. 61, Núm. 10, pp. 1867-1870

2012

  1. Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas

    International Journal of Cancer, Vol. 130, Núm. 11, pp. 2599-2606

2010

  1. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

    Clinical Cancer Research, Vol. 16, Núm. 17, pp. 4353-4362